Intermittent clobazam therapy and febrile seizure recurrence – A follow up study

---

Original Article

Author Details : Cyril Ignatious Rozario, Sunil Daniel*, Anzy N Saleem

Volume : 7, Issue : 1, Year : 2021

Article Page : 24-27

https://doi.org/10.18231/j.ijmpo.2021.006

Suggest article by email

Get Permission

---

Abstract

Objectives: To identify the proportion of children on intermittent clobazam therapy developing febrile seizure recurrence and to assess the risk factors of febrile seizure recurrence in children. 
Design: Descriptive follow up study.
Study setting: Children between 6 months to 5 years admitted in Govt.TDMCH for seizures associated with fever.
Materials and Methods: Children presenting with acute febrile seizures are started on intermittent clobazam therapy. The risk factors were assessed and study group is followed up for a period of one year. Data were analyzed using computer software SPSS. Data are expressed in its frequency and percentage as well as mean and standard deviation. To elucidate the associations and comparisons between different parameters, Chi square(X²) test was used as non-parametric test.
Results: Out of the 80 children followed up 28 children developed recurrence. Those who took clobazam had considerable reduction in recurrence (8.3% in clobazam group compared to 56.8% in those who were not on intermittent clobazam therapy. Complex febrile seizures (Odds ratio of 16.5 and p value <.01) and history of febrile seizures in the first degree relatives (Odds ratio of 3.81 and p value of <.01) had increased chance of recurrence.
Conclusion: Intermittent clobazam therapy has definite role in preventing febrile seizure recurrence. The risk factors for considering intermittent prophylaxis from this study are family history of febrile seizure and complex febrile seizure.

Keywords: Febrile seizure, Recurrence, Clobazam.

 

How to cite : Rozario C I, Daniel S , Saleem A N, Intermittent clobazam therapy and febrile seizure recurrence – A follow up study. IP Int J Med Paediatr Oncol 2021;7(1):24-27

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.